Statistics from Altmetric.com
Rivaroxaban or aspirin for extended treatment of venous thromboembolism
Many patients with venous thromboembolism (VTE) require extended treatment beyond the standard 6 months if they are felt to be at high risk of recurrence. It remains uncertain as to whether full or lower intensity anticoagulation is required. This randomised, double-blind, phase III trial (Weitz et al. N Engl J Med 2017;376:1211–22) compared once daily rivaroxaban at 20 mg or 10 mg doses with 100 mg of aspirin. Each patient had already completed 6–12 months of treatment dose anticoagulation therapy. A total of 3365 patients were included. The primary efficacy outcome was symptomatic recurrent VTE, and the principal safety outcome was major bleeding. The rate of symptomatic VTE was 1.5% in the 20 mg rivaroxaban group, 1.2% in the 10 mg rivaroxaban group and 4.4% in those receiving aspirin (p<0.001 for both rivaroxaban doses vs aspirin). Rates of major bleeding were 0.5% in the 20 mg rivaroxaban group and 0.4% in the 10 mg rivaroxban group and 0.3% in the aspirin group. Non-major bleeding rates were …
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.